New drug targets tough cancers with specific gene flaw
NCT ID NCT06364696
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called ASP4396 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug is given by IV infusion, and the main goals are to check safety, find the right dose, and see how the body handles it. About 175 participants will take part in two parts: dose escalation and dose expansion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASP4396
What this could lead to
If it works, this could lead to a new treatment option for people with certain hard-to-treat cancers that have a specific genetic mutation.
What could go wrong
This is a very early, first-in-human study, so the drug may not work or could cause serious side effects. It is only for people who have already tried other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
NEXT Oncology Dallas
Irving, Texas, 75039, United States
-
NEXT Oncology Virginia
Fairfax, Virginia, 22031, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
University of Rochester
Rochester, New York, 14627, United States